Active substance
Liothyronine
- US FDA 12
- Health Canada 8
- US price lines 5
- NHS prices 6
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CYTOMEL | EQ 0.005MG BASE; EQ 0.025MG BASE; EQ 0.05MG BASE | tablet · oral | KING PHARMS | Prescription | 8 May 1956 |
| LIOTHYRONINE SODIUM | EQ 0.01MG BASE/ML | injectable · injection | XGEN PHARMS | Prescription | 17 Aug 2005 |
| LIOTHYRONINE SODIUM | EQ 0.005MG BASE; EQ 0.025MG BASE; EQ 0.05MG BASE | tablet · oral | DR REDDYS LABS SA | Prescription | 20 Mar 2009 |
| LIOTHYRONINE SODIUM | EQ 0.005MG BASE; EQ 0.025MG BASE; EQ 0.05MG BASE | tablet · oral | SIGMAPHARM LABS LLC | Prescription | 29 Nov 2012 |
| LIOTHYRONINE SODIUM | EQ 0.005MG BASE; EQ 0.025MG BASE; EQ 0.05MG BASE | tablet · oral | SUN PHARM | Prescription | 20 Apr 2016 |
| LIOTHYRONINE SODIUM | EQ 0.005MG BASE; EQ 0.025MG BASE; EQ 0.05MG BASE | tablet · oral | TEVA PHARMS USA | Prescription | 26 Oct 2018 |
| LIOTHYRONINE SODIUM | EQ 0.005MG BASE; EQ 0.025MG BASE; EQ 0.05MG BASE | tablet · oral | ZYDUS LIFESCIENCES | Prescription | 22 Jan 2021 |
| LIOTHYRONINE SODIUM | EQ 0.005MG BASE; EQ 0.025MG BASE; EQ 0.05MG BASE | tablet · oral | BIOCON PHARMA | Prescription | 6 Feb 2024 |
| LIOTHYRONINE SODIUM | EQ 0.025MG BASE | tablet · oral | WATSON LABS | Discontinued | 25 Jan 1982 |
| LIOTHYRONINE SODIUM | EQ 0.05MG BASE | tablet · oral | WATSON LABS | Discontinued | 3 Feb 1982 |
| TRIOSTAT | EQ 0.01MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | PH HEALTH | Discontinued | 31 Dec 1991 |
| LIOTHYRONINE SODIUM | EQ 0.005MG BASE; EQ 0.025MG BASE; EQ 0.05MG BASE | tablet · oral | PHARMOBEDIENT | Discontinued | 14 Jul 2009 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AURO-LIOTHYRONINE | 02549999 | 5 MCG | TABLET · ORAL | AURO PHARMA INC |
| AURO-LIOTHYRONINE | 02550008 | 25 MCG | TABLET · ORAL | AURO PHARMA INC |
| CYTOMEL | 01919458 | 5 MCG | TABLET · ORAL | PFIZER CANADA ULC |
| CYTOMEL | 01919466 | 25 MCG | TABLET · ORAL | PFIZER CANADA ULC |
| TEVA-LIOTHYRONINE | 02494337 | 5 MCG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-LIOTHYRONINE | 02494345 | 25 MCG | TABLET · ORAL | TEVA CANADA LIMITED |
| ZDS-LIOTHYRONINE | 02561298 | 5 MCG | TABLET · ORAL | ZYDUS LIFESCIENCES LIMITED |
| ZDS-LIOTHYRONINE | 02561301 | 25 MCG | TABLET · ORAL | ZYDUS LIFESCIENCES LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CYTOMEL 25 MCG TABLET | $0.53303 | per EA | 23 Sep 2026 |
| US NADAC | CYTOMEL 5 MCG TABLET | $0.3857 | per EA | 23 Sep 2026 |
| US NADAC | LIOTHYRONINE SOD 25 MCG TAB | $0.29408 | per EA | 23 Sep 2026 |
| US NADAC | LIOTHYRONINE SOD 5 MCG TAB | $0.2023 | per EA | 23 Sep 2026 |
| US NADAC | LIOTHYRONINE SOD 50 MCG TAB | $0.36222 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Liothyronine 10microgram capsules | £65.00 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Liothyronine 10microgram tablets | £152.44 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Liothyronine 20microgram capsules | £55.00 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Liothyronine 20microgram tablets | £18.86 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Liothyronine 5microgram capsules | £55.00 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Liothyronine 5microgram tablets | £35.79 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.